Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Adrian Murray Brunt"'
Publikováno v:
Breast, Vol 69, Iss , Pp 410-416 (2023)
This overview provides the historical perspective of external beam breast hypofractionation over the last 50 years. It highlights the serious harm suffered by patients with breast cancer in the 1970's and 1980's because of new hypofractionation regim
Externí odkaz:
https://doaj.org/article/768a7f799b1348d6bc90d8d294f87ed9
Autor:
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, David J Bloomfield, Charlie Chan, Suzy Cleator, Charlotte E Coles, Ellen Donovan, Helen Fleming, David Glynn, Andrew Goodman, Susan Griffin, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Zohal Nabi, Jaymini Patel, Elinor Sawyer, Navita Somaiah, Isabel Syndikus, Karen Venables, John R Yarnold, Judith M Bliss
Publikováno v:
Health Technology Assessment, Vol 27, Iss 25 (2023)
Background FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard 15-fraction regimen after primary surgery for early breast
Externí odkaz:
https://doaj.org/article/1d13e92e28404c31aa757bc6060cebd9
Autor:
Jenny Ingram, Lucy Beasant, John Benson, Adrian Murray Brunt, Anthony Maxwell, James Richard Harvey, Rosemary Greenwood, Nicholas Roberts, Norman Williams, Debbie Johnson, Zoe Winters
Publikováno v:
Pilot and Feasibility Studies, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Background A multicentre feasibility trial (MIAMI), comparing outcomes and quality of life of women with multiple ipsilateral breast cancer randomised to therapeutic mammoplasty or mastectomy, was conducted from September 2018 to March 2020.
Externí odkaz:
https://doaj.org/article/a8b1ac9e96d1431999e07cf5fe5728bb
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Supplementary Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2582b40e3e9fb5fd63904f027e23fca8
https://doi.org/10.1158/1078-0432.22487985
https://doi.org/10.1158/1078-0432.22487985
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc8932db29ed31281a0cffa784eab54
https://doi.org/10.1158/1078-0432.22487964
https://doi.org/10.1158/1078-0432.22487964
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Purpose:EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer.Patients and Methods:This randomized phase II, two-part, multicenter trial included newly dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735de3c465e80978154bc41d4f2e3c63
https://doi.org/10.1158/1078-0432.c.6532623.v1
https://doi.org/10.1158/1078-0432.c.6532623.v1
Autor:
Ailsa J. Oswald, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John Bartlett, Tammy Piper, Eve Macdonald Chisholm, Michelle Welsh, Robert Hill, Lisa E. M. Hopcroft, Peter Barrett-Lee, David A. Cameron
Publikováno v:
Oswald, A, Symeonides, S N, Wheatley, D, Chan, S, Murray Brunt, A, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Macdonald Chisholm, E, Welsh, M, Hill, R, Hopcroft, L E, Barrett-Lee, P & Cameron, D A 2023, ' ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-023-06873-8
Purpose The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05748b6217c9d05f9fb0f6d40ba51272
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
Autor:
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, Abeer Shaaban, Emad Rakha, Anne Armstrong, Ramsey Cutress, David Dodwell, Marie Emson, Abigail Evans, Sue Hartup, Kieran Horgan, Stuart McIntosh, Jay Naik, Samkaran Narayanan, Jane Oii, Anthony Skene, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:P2-13
Background: EPHOS-B is a multi-centre randomized trial designed to investigate whether anti-HER2 therapy given 11 days pre-surgery inhibited proliferation and/or increased apoptosis in HER2-positive early breast cancer. Significant differences in Ki6
Autor:
David Glynn, Judith Bliss, Adrian Murray Brunt, Charlotte E. Coles, Duncan Wheatley, Joanne S. Haviland, Anna M. Kirby, Francesco Longo, Rita Faria, John R. Yarnold, Susan Griffin
Purpose We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in ei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a00da41a799b209ddcf85bca2fb7fc
Autor:
Madeleine T King, Emma K Link, Tim J Whelan, Ivo A Olivotto, Ian Kunkler, Antonia Helen Westenberg, Guenther Gruber, Penny Schofield, Boon H Chua, Claire Phillips, Guy Bryant, Helen Westenberg, Om Pra-Kesh Purohit, Verity Ahern, Peter Graham, Mohamed Akra, Orla McArdle, Peter O'Brien, Jane Ludbrook, Jennifer Harvey, John H Maduro, Isabelle Gabelle-Flandin, Carine Kirkove, Carolyn Bedi, Joseph Martin, Tony Vu, Theirry Muanza, Anthony Neal, Adel Courdi, Juliette Thariat, Eileen Rakovitch, Laurien Daniels, Marjan van Hezewijk, Wlasyslawa Cwajna, Adelheid Roelstraete, Angela van Baardwijk, Nicola Russel, Anne Koch, Jennifer Croke, Imogen Locke, Peter Jeal, Quenten Walker, Kandeepeepan Thuraisingham, Anupam Chauduri, David Joseph, Mandy Taylor, Sabine Vanderkam, Tony Woo, Johann Tang, Michael Yassa, Elaine Wai, Susan Hewitt, Shazia Mahmood, Jennifer Gilmore, Bolante Ofi, Amit Bahl, Olga Vujovic, Edward Yu, Duc Le, Iwa Kong, Alan Nichol, Nina Bijker, Geoff Delaney, Malcolm Feigen, Adeline Lim, Michael Chao, Margaret Latham, Hafiz Algurafi, Christoph Tausch, Eric Khoo, Sam Leung, Karen Taylor, Sasha Senthi, Andrea Stevens, Abhro Chaudhuri, Susan Cleator, Adrian Murray Brunt, Scott Babington, David Christie, Daniel Zwahlen, Ulrich Schratzenstaller, Laurence Masson, Nicola Storey, Eshwar Kumar, Liz Sherwin, Reinhilde Weytjens, Sharma Ravi, Patricia Lawton, Ruth Angell, Glenys Round, Angela Allen, Ziad Thotathil, Margaret Anthes, Christiane Reuter, Laura Pettit, Yvonne Zissiadis, Christine Elder, Antoinette Verbeek-de Kanter, Andree Lirette, Ludwig Plasswilm, David Spooner, Fiona Hoar, Islam Mohamed, Kristina Lossl, Vivienne Loo, Antonella Richetti, Tamasin Evans, Aisling Hennessy, Medhat El-Mallah, Marketa Skala, Raef Awad, Isabelle Germain, Carine Mitine, Hilde Van Parijs, Mark Churn, Nawaz Walji, Michael Francis, Karin Stellamans, Gunther Gruber, Giovanni Ivaldi, Abdulla Alhasso, Lizbeth Kenny, Ken Tiver, Matthew Griffin, Gillian Lamoury, Marco Trovo, Hafiz Algufarfi, Minjae Lah, Scott Carruthers, George Papadatos, Gabriel Paardekooper, Mojca Persic, Bernadette Lavery
Publikováno v:
lancet oncology, 21(5), 685-698. Lancet Publishing Group
Summary Background BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surger